Hemodialyzer guidance
This article was originally published in The Gray Sheet
Executive Summary
510(k)s for conventional (21 CFR 876.5820) and high-permeability (21 CFR 876.5860) hemodialyzers that have "new" membrane material or employ a design that is "significantly different" from the predicate device should include clinical data "collected on a minimum of 12 patients for a minimum of 36 treatments," FDA says in a guidance document posted Sept. 23 on its website (www.fda.gov/cdrh). For hemodialyzers labeled "single use only," clinical data "on a minimum of 12 patients" should be included to "clarify the relationship between the ultrafiltration data obtained from the in vitro tests and the expected clinical performance of the hemodialyzer," the agency says
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.